http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Press+Releases/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495 http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html <p align="justify">VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “<strong>Company</strong>” or “<strong>Grey Matters</strong>”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. http://www.streetinsider.com/Globe+Newswire/Grey+Matters+Health+Signs+LOI+with+Catalyst+MedTech+for+200+Brain+PET+Scans+for+Alzheimer%E2%80%99s+Clinical+Trial+at+2nd+NovaScan+Location+Planned+for+Tampa/26524610.html Wed, 20 May 2026 07:00:00 -0400 AGN AGNPF AGW0 GREY O.31280495